aTyr Pharma(LIFE) - 2024 Q4 - Annual Results

Financial Performance - Total revenues for the year ended 2024 were $0.235 million, a decrease from$0.353 million in 2023[15]. - The consolidated net loss for the year ended 2024 was $64.0 million, compared to a net loss of$50.4 million in 2023[15]. - Research and development expenses for the year ended 2024 were $54.4 million, primarily for clinical trial costs[8]. - General and administrative expenses for the year ended 2024 were$13.8 million[8]. Cash and Assets - Cash and cash equivalents as of December 31, 2024, were $75.1 million, with an additional$18.8 million raised post-Q4 2024[8]. - Total assets decreased from $120,653 million in 2023 to$96,830 million in 2024, representing a decline of approximately 19.7%[17]. - Cash and cash equivalents dropped from $101,650 million in 2023 to$75,076 million in 2024, a decrease of about 26.1%[17]. - Total stockholders' equity fell from $90,470 million in 2023 to$69,832 million in 2024, reflecting a decline of approximately 22.8%[17]. - Accounts payable and accrued expenses decreased from $15,088 million in 2023 to$13,715 million in 2024, a reduction of about 9.1%[17]. - Long-term operating lease liability, net of current portion, decreased from $12,339 million in 2023 to$11,144 million in 2024, a decline of approximately 9.7%[17]. - Prepaid expenses and other assets increased significantly from $2,521 million in 2023 to$8,159 million in 2024, an increase of about 223.5%[17]. - Current portion of financing lease liability increased from $497 million in 2023 to$541 million in 2024, an increase of approximately 8.8%[17]. - Current portion of operating lease liability decreased from $831 million in 2023 to$711 million in 2024, a reduction of about 14.4%[17]. - Other receivables decreased from $2,436 million in 2023 to$1,736 million in 2024, a decline of approximately 28.8%[17]. - Financing lease right-of-use assets decreased from $1,788 million in 2023 to$1,192 million in 2024, a decline of about 33.4%[17]. Clinical Trials - Topline data from the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis is expected in Q3 2025[1]. - The Phase 3 EFZO-FIT™ study enrolled 268 patients across 85 centers in nine countries, with a total of 12 doses administered[5]. - The fourth positive DSMB review for efzofitimod confirmed its favorable safety profile, allowing the study to continue as designed[4]. - Interim data from the Phase 2 EFZO-CONNECT™ study is expected in Q2 2025, focusing on skin assessments in approximately 8 patients[6]. Financial Guidance - The company updated its financial guidance, indicating sufficient cash runway for one year following the Phase 3 EFZO-FIT™ readout[8].